270 related articles for article (PubMed ID: 37376135)
1. The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers.
Andrade F; German-Cortés J; Montero S; Carcavilla P; Baranda-Martínez-Abascal D; Moltó-Abad M; Seras-Franzoso J; Díaz-Riascos ZV; Rafael D; Abasolo I
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376135
[TBL] [Abstract][Full Text] [Related]
2. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
Rafael D; Montero S; Carcavilla P; Andrade F; German-Cortés J; Diaz-Riascos ZV; Seras-Franzoso J; Llaguno M; Fernández B; Pereira A; Duran-Lara EF; Schwartz S; Abasolo I
ACS Appl Mater Interfaces; 2023 Mar; 15(8):10398-10413. PubMed ID: 36795046
[TBL] [Abstract][Full Text] [Related]
4. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
5. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
6. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer.
Sunaga N; Miura Y; Kasahara N; Sakurai R
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885068
[TBL] [Abstract][Full Text] [Related]
7. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
8. The Therapeutic Landscape for
Tria SM; Burge ME; Whitehall VLJ
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190303
[TBL] [Abstract][Full Text] [Related]
9. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.
Ritu K; Kumar P; Singh A; Nupur K; Spalgias S; Mrigpuri P; Rajkumar
Mol Biomed; 2021 Dec; 2(1):40. PubMed ID: 34918209
[TBL] [Abstract][Full Text] [Related]
10. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
[No Abstract] [Full Text] [Related]
12. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
13. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
14. Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog -mutant colorectal cancer.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Biochem; 2019 Feb; 120(2):1106-1121. PubMed ID: 30362665
[TBL] [Abstract][Full Text] [Related]
15. Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.
Niloy MS; Shakil MS; Alif MMH; Rosengren RJ
Curr Med Chem; 2021; 28(39):8098-8115. PubMed ID: 33645474
[TBL] [Abstract][Full Text] [Related]
16. Targeting
Mustachio LM; Chelariu-Raicu A; Szekvolgyi L; Roszik J
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801965
[TBL] [Abstract][Full Text] [Related]
17. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
[TBL] [Abstract][Full Text] [Related]
18. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of KRAS in human cancers.
Jancík S; Drábek J; Radzioch D; Hajdúch M
J Biomed Biotechnol; 2010; 2010():150960. PubMed ID: 20617134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
